United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®
10,350,180 for an enhanced formulation of Pliaglis which provides extended patent protection until 2031.
- 10,350,180 for an enhanced formulation of Pliaglis which provides extended patent protection until 2031.
- "The newly granted U.S. patent further strengthens our intellectual property portfolio," said Serge Verreault, President and CEO of Crescita.
- In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking statements.
- Forward-looking statements are not historical facts but instead represent management's expectations, estimates, projections and assumptions regarding future events or circumstances.